Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tectonic Therapeutic (TECX) EBITDA (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of EBITDA data on record, last reported at -$27.3 million in Q1 2026.

  • On a quarterly basis, EBITDA fell 49.2% to -$27.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$93.0 million, a 46.87% decrease, with the full-year FY2025 number at -$84.0 million, down 44.85% from a year prior.
  • EBITDA reached -$27.3 million in Q1 2026 per TECX's latest filing, down from -$21.5 million in the prior quarter.
  • Over the last five years, EBITDA for TECX hit a ceiling of -$9.4 million in Q4 2023 and a floor of -$29.8 million in Q1 2022.
  • A 5-year average of -$19.5 million and a median of -$21.5 million in 2025 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: surged 62.89% in 2023, then crashed 95.53% in 2025.
  • Tracing TECX's EBITDA over 5 years: stood at -$25.3 million in 2022, then soared by 62.89% to -$9.4 million in 2023, then crashed by 49.25% to -$14.0 million in 2024, then tumbled by 53.78% to -$21.5 million in 2025, then dropped by 26.89% to -$27.3 million in 2026.
  • Business Quant data shows EBITDA for TECX at -$27.3 million in Q1 2026, -$21.5 million in Q4 2025, and -$21.9 million in Q3 2025.